Table 3.

Safety summary in the Canadian subpopulation (All-Subjects-as-Treated)

AE, No. (%)	Ragweed SLIT-tablet (n = 117)*	Placebo (n = 129)*
Treatment-emergent AE	108 (92.3)	96 (74.4)
Treatment-related AE	89 (76.1)	47 (36.4)
SAE	0	0
Treatment-related SAE	0	0
AE leading to treatment discontinuation	6 (5.1)	0
Treatment-related AE leading to treatment discontinuation	6 (5.1)	0
Discontinued treatment due to SAE	0	0
Discontinued treatment due to a treatment-related SAE	0	0

AE adverse event, SAE serious adverse event

^*One subject randomized to placebo received the ragweed SLIT-tablet by mistake